Innate Pharma SA announces today its financial results for the first half of 2010.
Half-year report on INNATE PHARMA’S liquidity contract with NATIXIS SECURITIES
Final data on response rate for the Phase II trial with IPH 1101 in Follicular Lymphoma reported at the EHA meeting
Innate Pharma announces its participation to major upcoming medical meetings
Innate Pharma announces the outcome of its annual general meeting, as well as changes in the composition of its management and governance bodies
Innate Pharma releases its total number of shares outstanding as well as its voting rights as at April 30, 2010
Innate Pharma announces its turnover for the first quarter of 2010 and updates on its cash situation
Innate Pharma announces the release of its annual report and reference document (in French)
Innate Pharma to hold its Annual General Meeting of Shareholders on May 25, 2010, in Marseilles, France
Number of shares outstanding and voting rights, as of March 31, 2010
